Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune System Diseases 1AIDS-Related Complex 1

Interventions

ponatinib 4fludarabine 4Cyclophosphamide 3fludarabine phosphate 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Imatinib Mesylate 2Busulfan 2Bone Marrow Transplantation 2trametinib 1tetulomab tetraxetan lu-177 1ruxolitinib 1pertuzumab 1nirogacestat 1nilotinib 1gilteritinib 1emvododstat 1dabrafenib 1bosutinib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × tetulomab tetraxetan lu-177 × Other hematologic neoplasm × Clear all
NCT02657447 2019-01-10

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Nordic Nanovector

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

AIDS-Related Complex, Immune System Diseases, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡